Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W Bialymstoku samodzielny publiczny zakład opieki zdrowotnej
- Address
- lock Available on a paid plan
Neoplasms and Pediatric Blood Cancer Research
At Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W Bialymstoku samodzielny publiczny zakład opieki zdrowotnej, clinical research in the Neoplasms area focuses on serious childhood cancers, especially acute lymphoblastic leukemia in infants. The trials are aimed at improving treatment outcomes and long-term survival for very young patients.
- Studying infant acute lymphoblastic leukemia to improve event-free survival and strengthen treatment results
- Evaluating new approaches for newly diagnosed KMT2A-rearranged leukemia in pediatric oncology
- Supporting research on better cancer care for infants through more effective therapy strategies
This work reflects the site’s active role in pediatric oncology, with a clear emphasis on testing therapies that may offer better disease control and future outcomes for children.
Hormonal Diseases and Pediatric Endocrinology
The department also conducts research in Hormonal Diseases, with a strong focus on idiopathic growth hormone deficiency in children. These trials are designed to assess the long-term safety of treatment and help clarify how well children respond over time.
- Following children with idiopathic growth hormone deficiency to better understand treatment safety and durability
- Exploring endocrine care options that may support healthier growth in pediatric patients
- Contributing to evidence on the long-term use of therapies for growth hormone deficiency
Research in this area combines pediatric endocrinology and patient safety, helping clinicians refine care for children living with growth-related hormonal disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 14 therapeutic areas and 15 of 82 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 81 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1GPOH gGmbH2active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH2trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W Bialymstoku samodzielny publiczny zakład opieki zdrowotnej
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 82 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 6 | Unknown | 2019-08-01 | 2024-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.